Cargando…
Current status and progress in immunotherapy for malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease. Currently, the platinum doublet of pemetrexed and cisplatin is the standard first‐line treatment for unresectable MPM. However, recent promising results of immunotherapy have markedly changed the landscape of MPM treatm...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215716/ https://www.ncbi.nlm.nih.gov/pubmed/35774429 http://dx.doi.org/10.1002/cdt3.18 |